Key result
Elevated hsTnT linked to ~117% greater cardiovascular mortality in adults 70-95, independent of CVD.
Why the study?
It remained unclear whether high-sensitivity cardiac troponin T (hsTnT) independently predicts mortality in older adults.
Does elevated high-sensitivity cardiac troponin T (hsTnT) predict all-cause and cardiovascular mortality in a mobile cohort of older adults aged 70 to 95 years?
Does elevated high-sensitivity cardiac troponin T (hsTnT) predict all-cause and cardiovascular mortality in a mobile cohort of older adults aged 70 to 95 years?
Elevated high-sensitivity cardiac troponin T is a strong independent predictor of both cardiovascular and non-cardiovascular mortality in older adults, including those with prevalent cardiovascular disease.
May warrant hsTnT for risk assessment in adults 70-95; extends independent prognostic value to this mobile elderly cohort regardless of CVD.
It remains unclear whether high-sensitivity cardiac troponin T (hsTnT) independently predicts mortality in older adults. To estimate mortality rate and association of hsTnT with all-cause and cardiovascular death in the older, mobile population. This analysis was conducted in 2,055 subjects of the AugUR-study, a prospective population-based cohort study in individuals aged 70 years and older with up to 10-year mortality follow-up. We used Cox proportional hazard models to estimate hazard ratios (HR) and 95% confidence intervals (CI) for association of hsTnT with all-cause, cardiovascular, non-cardiovascular and premature mortality risk. Association results of hsTnT with mortality were reported for tertiles and per 1 standard deviation (SD) of log-transformed values. Participants were 70 to 95 years old with 48% men and 56% with prevalent cardiovascular disease (CVD). In a median follow-up period of 6.0 years, 385 (113 cardiovascular) deaths were recorded. For all-cause mortality, HR was 1.66 [95%CI=1.49-1.85] after adjustment for age and sex (p-value<0.001). For cardiovascular mortality, the effect was more pronounced (HR=2.17 [95%CI=1.79-2.63]; p<0.001). The association between hsTnT with non-cardiovascular mortality was also significant (HR=1.61 [95%CI=1.41-1.83]; p<0.001). In a full model adjusting for factors influencing mortality and hsTnT levels, in participants with prevalent CVD, hsTnT showed still association with cardiovascular mortality (HR=1.65 [95%CI=1.30-2.10]; p<0.001) but also with non-cardiovascular mortality (HR=1.32 [95%CI=1.10-1.58]; p<0.01). Elevated levels of hsTnT were associated with increased cardiovascular and non-cardiovascular mortality risk in an old-aged population. Measurement of hsTnT in subjects with prevalent CVD may help identify individuals at high risk for mortality.
No takes yet. Share an insight, caveat, or question.
Klaus et al. (2026) studied this question. Elevated hsTnT was associated with increased cardiovascular mortality (HR=2.17) and all-cause mortality (HR=1.66) in adults aged 70-95, independent of CVD status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: